7.890USDMkt Cap: 73.76M USDP/E: —Last update: 2026-05-21
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prul…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap73.76M USD
Enterprise Value-49.94M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-116.80M USD
Revenue/Share—
Last Price7.890 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees102
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS0070021086
Valuation
P/E (Trailing)—
P/E (Forward)-1.88
PEG—
EV/EBITDA0.46
EV/Revenue—
P/S—
P/B0.54
EPS (TTM)-13.87
EPS (Forward)-4.19
52W Range
7.47075% of range8.030
52W High8.030 USD
52W Low7.470 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-73.36%
ROA-60.72%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-95.25M USD
CapEx (TTM)1.74M USD
FCF Margin—
FCF Yield-65.76%
Net Debt-123.69M USD
Net Debt/EBITDA1.15
Balance Sheet
Debt/Equity0.09
Current Ratio7.66
Quick Ratio7.52
Book Value/Sh14.59 USD
Cash/Share14.72 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateSep 16, 2020
Splits
Last Split1:16
Split DateDec 30, 2025
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)34.83 USD
Target Range18.00 USD – 100.00 USD
# Analysts6
Ownership
Shares Out.9.35M
Float5.83M
Insiders0.92%
Institutions63.57%
Short Interest
Short Ratio4.0d
Short % Float5.94%
Short % Out.5.92%
Shares Short553.51K
Short (prev mo.)656.55K
Technical
SMA 507.472 (+5.6%)
SMA 2009.538 (-17.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)105.74K
Avg Vol (10d)123.09K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—